READING, 12th September 2008 – Archimedes Pharma Ltd (“Archimedes”), the UK-based pan-European specialty pharmaceutical company, announces it has appointed Andrew Morris as UK Country Manager.
Andrew joined Archimedes’ UK organisation in April as Marketing Director, Critical Care from ProStrakan. Andrew’s previous roles at ProStrakan included Head of International Marketing for the cancer supportive care portfolio and Head of Marketing UK. His career in the pharmaceutical industry has also included roles at Novo Nordisk, Parke Davis and UCB Pharma.
As a member of Archimedes’ successful UK Management Team, Andrew has been involved in a business which has delivered significant growth across a portfolio of specialty products including Gliadel® for high-grade glioma, Zomorph for pain, Nozinan for supportive therapy in cancer patients, and Pabrinex for acute alcohol problems.
Simon Collins, previously UK Country Manager, is leaving Archimedes to pursue another career opportunity. He will be supporting Archimedes on a number of projects until the end of October.
Andrew’s experience of the UK market, and track record, provided us with an excellent candidate to appoint in this position upon of Simon Collins’ departure,
Richard de Souza, CEO of Archimedes, said: “Andrew has made an excellent contribution to Archimedes since joining the company and I am confident that he will continue to do so as UK Country Manager. Our UK business has shown strong growth in the last two years, driven by increased focus and efficiency. This growth is set to continue with a number of new product launches planned in the near and medium term, ahead of the planned launch of our lead product NasalFent® for breakthrough cancer pain which has blockbuster potential. We welcome Andrew to his new role and thank Simon for the part he has played in the success of Archimedes thus far and wish him well in the future.”
